Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Astellas Pharma Inc.
DescriptionAntibody-drug conjugate (ADC) composed of an anti-SLIT and NTRK-like family member 6 (SLITRK6) mAb and monomethyl auristatin E (MMAE)
Molecular Target SLIT and NTRK-like family member 6 (SLITRK6)
Mechanism of ActionAntibody-drug conjugate
Therapeutic ModalityBiologic: Antibody-drug conjugate
Latest Stage of DevelopmentPhase I
Standard IndicationBladder cancer
Indication DetailsTreat bladder cancer; Treat metastatic urothelial cancer
Regulatory Designation
PartnerSeattle Genetics Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today